Daiwa Securities Group Portfolio holdings
AUM
$27.1B
1-Year Return
23.24%
This Quarter Return
+15.72%
1 Year Return
+23.24%
3 Year Return
+64.59%
5 Year Return
+118.48%
10 Year Return
+210.79%
AUM
$11.4B
AUM Growth
+$1.02B
(+9.8%)
Cap. Flow
-$832M
Cap. Flow
% of AUM
-7.27%
Top 10 Holdings %
Top 10 Hldgs %
38.52%
Holding
1,212
New
71
Increased
449
Reduced
354
Closed
26
Top Buys
| 1 |
Public Storage
PSA
|
$260M |
| 2 |
Equinix
EQIX
|
$114M |
| 3 |
Extra Space Storage
EXR
|
$67M |
| 4 |
Invitation Homes
INVH
|
$52.9M |
| 5 |
Pebblebrook Hotel Trust
PEB
|
$41.3M |
Top Sells
| 1 |
Vornado Realty Trust
VNO
|
$173M |
| 2 |
Crown Castle
CCI
|
$132M |
| 3 |
SBA Communications
SBAC
|
$106M |
| 4 |
Healthpeak Properties
DOC
|
$104M |
| 5 |
Ventas
VTR
|
$103M |
Sector Composition
| 1 | Real Estate | 74.35% |
| 2 | Technology | 3.93% |
| 3 | Industrials | 3.02% |
| 4 | Financials | 2.66% |
| 5 | Healthcare | 2.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
976
Myriad Genetics
MYGN
$615M
| $15K | ﹤0.01% |
466
+83
| +22% | +$2.67K |
|
|
XLRN
977
DELISTED
Acceleron Pharma Inc.
XLRN
| $15K | ﹤0.01% |
329
+79
| +32% | +$3.6K |
|
|
PTLA
978
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $15K | ﹤0.01% |
422
+61
| +17% | +$2.17K |
|
|
ZGNX
979
DELISTED
Zogenix, Inc.
ZGNX
| $15K | ﹤0.01% |
268
+79
| +42% | +$4.42K |
|
980
Halozyme
HALO
$8.76B
| $15K | ﹤0.01% |
922
+135
| +17% | +$2.2K |
|
981
Denali Therapeutics
DNLI
$2.26B
| $14K | ﹤0.01% |
604
-161
| -21% | -$3.73K |
|
982
Insmed
INSM
$30.7B
| $14K | ﹤0.01% |
493
+70
| +17% | +$1.99K |
|
983
PTC Therapeutics
PTCT
$4.55B
| $14K | ﹤0.01% |
365
+136
| +59% | +$5.22K |
|
984
uniQure
QURE
$985M
| $14K | ﹤0.01% |
+239
| New | +$14K |
|
|
AERI
985
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $14K | ﹤0.01% |
289
+86
| +42% | +$4.17K |
|
|
ARNA
986
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $14K | ﹤0.01% |
315
-52
| -14% | -$2.31K |
|
987
AnaptysBio
ANAB
$613M
| $13K | ﹤0.01% |
172
+42
| +32% | +$3.17K |
|
988
Medpace
MEDP
$13.7B
| $13K | ﹤0.01% |
227
+19
| +9% | +$1.09K |
|
989
Regenxbio
RGNX
$490M
| $13K | ﹤0.01% |
232
+60
| +35% | +$3.36K |
|
|
RETA
990
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $13K | ﹤0.01% |
153
+43
| +39% | +$3.65K |
|
|
MYOK
991
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $13K | ﹤0.01% |
256
+58
| +29% | +$2.95K |
|
|
MDCO
992
DELISTED
Medicines Co
MDCO
| $13K | ﹤0.01% |
470
-19,933
| -98% | -$551K |
|
993
Atara Biotherapeutics
ATRA
$90.7M
| $12K | ﹤0.01% |
12
+4
| +50% | +$4K |
|
994
CRISPR Therapeutics
CRSP
$4.99B
| $12K | ﹤0.01% |
332
+78
| +31% | +$2.82K |
|
995
Enanta Pharmaceuticals
ENTA
$189M
| $12K | ﹤0.01% |
124
+19
| +18% | +$1.84K |
|
996
Supernus Pharmaceuticals
SUPN
$2.58B
| $12K | ﹤0.01% |
332
+49
| +17% | +$1.77K |
|
|
ENDP
997
DELISTED
Endo International plc
ENDP
| $11K | ﹤0.01% |
+1,427
| New | +$11K |
|
|
ALLK
998
DELISTED
Allakos
ALLK
| $11K | ﹤0.01% |
268
-32
| -11% | -$1.31K |
|
999
Arrowhead Research
ARWR
$4.02B
| $11K | ﹤0.01% |
599
+122
| +26% | +$2.24K |
|
1000
Copel
ELP
$6.77B
| $11K | ﹤0.01% |
3,000
-1,000
| -25% | -$3.67K |
|